H.C. Wainwright analyst Yi Chen reiterated a Buy rating on LifeMD (LFMD – Research Report) today and set a price target of $14.00.
Yi Chen has given his Buy rating due to a combination of factors that highlight LifeMD’s strong financial performance and growth potential. The company reported impressive revenue growth in the fourth quarter of 2024, with total revenue surpassing expectations and telehealth revenue showing a significant year-over-year increase. This robust financial performance is complemented by a growing active subscriber base, indicating a healthy demand for LifeMD’s services.
Additionally, LifeMD’s comprehensive care platform and upcoming product launches in 2025 are expected to further bolster its market position. The integration with LillyDirect and the expansion into virtual behavioral and women’s health offerings demonstrate the company’s strategic initiatives to enhance its service offerings. Furthermore, LifeMD’s positive operating cash flows and adjusted EBITDA figures suggest a stable financial footing, supporting the decision to maintain a Buy rating and raise the price target to $14 per share.
In another report released yesterday, KeyBanc also maintained a Buy rating on the stock with a $7.50 price target.
Questions or Comments about the article? Write to editor@tipranks.com